Latest News and Press Releases

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Necrotizing Enterocolitis Market - A Global and Regional Analysis: Focus on Treatment Type, Diagnosis, End User, Country, and Region - Analysis and...

Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses...

Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens...

Dublin, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The "Gastroenterology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Gastroenterology was...

FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...

Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to...

Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Gastroenterology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Gastroenterology was...

VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA...

New data includes real-world analyses of VOQUEZNA-treated patients in the U.S. diagnosed with gastroesophageal reflux disease (GERD) FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom...